African health sciences · 2024
Comparison of eptinezumab 300 mg with 100 mg for the treatment of migraine: a meta-analysis of randomized controlled studies.
СтатьяМетаанализСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Jing, Li Xingchuan, Yang Zhiguo, Baowang Yang, Zhang Ni
Аннотация
INTRODUCTION: The efficacy and safety of eptinezumab 300 mg versus 100 mg for migraine remains debatable. We conduct this meta-analysis to compare eptinezumab 300 mg with 100 mg on the treatment of migraine.
METHODS: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through April 2021 for randomized controlled trials (RCTs) assessing the effect of eptinezumab 300 mg versus 100 mg on treatment efficacy and safety in migraine patients. This meta-analysis was performed using the random-effect model.
RESULTS: Four RCTs were included in the meta-analysis. Overall, compared with eptinezumab 100 mg in migraine patients, eptinezumab 300 mg was associated with substantially improved 75% responder rate (OR=1.34; 95% CI=1.06 to 1.69; P=0.01), but demonstrated similar monthly migraine days (MD=-0.09; 95% CI=-0.20 to 0.01; P=0.08), 100% responder rate (OR=1.38; 95% CI=0.94 to 2.02; P=0.10), 50% responder rate (OR=1.20; 95% CI=0.97 to 1.48; P=0.10), migraine 1 day after dosing (OR=0.92; 95% CI=0.72 to 1.18; P=0.52), adverse events (OR=1.13; 95% CI=0.77 to 1.65; P=0.53), nasopharyngitis (OR=1.26; 95% CI=0.74 to 2.14; P=0.40), upper respiratory tract infection (OR=1.25; 95% CI=0.83 to 1.88; P=0.29), sinusitis (OR=1.78; 95% CI=0.95 to 3.33; P=0.07) or nausea (OR=1.26; 95% CI=0.68 to 2.32; P=0.46).
CONCLUSIONS: Eptinezumab 300 mg may have better efficacy for migraine patients than eptinezumab 100 mg.
METHODS: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through April 2021 for randomized controlled trials (RCTs) assessing the effect of eptinezumab 300 mg versus 100 mg on treatment efficacy and safety in migraine patients. This meta-analysis was performed using the random-effect model.
RESULTS: Four RCTs were included in the meta-analysis. Overall, compared with eptinezumab 100 mg in migraine patients, eptinezumab 300 mg was associated with substantially improved 75% responder rate (OR=1.34; 95% CI=1.06 to 1.69; P=0.01), but demonstrated similar monthly migraine days (MD=-0.09; 95% CI=-0.20 to 0.01; P=0.08), 100% responder rate (OR=1.38; 95% CI=0.94 to 2.02; P=0.10), 50% responder rate (OR=1.20; 95% CI=0.97 to 1.48; P=0.10), migraine 1 day after dosing (OR=0.92; 95% CI=0.72 to 1.18; P=0.52), adverse events (OR=1.13; 95% CI=0.77 to 1.65; P=0.53), nasopharyngitis (OR=1.26; 95% CI=0.74 to 2.14; P=0.40), upper respiratory tract infection (OR=1.25; 95% CI=0.83 to 1.88; P=0.29), sinusitis (OR=1.78; 95% CI=0.95 to 3.33; P=0.07) or nausea (OR=1.26; 95% CI=0.68 to 2.32; P=0.46).
CONCLUSIONS: Eptinezumab 300 mg may have better efficacy for migraine patients than eptinezumab 100 mg.